These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11995208)

  • 21. [Hepatic abscess due to Yersinia in a child with thalassemia].
    Brunel F; François P; Durand C; Croize J; Jeannoel P
    Pediatrie; 1993; 48(2):159-62. PubMed ID: 8393182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurophysiologic evaluation of long-term desferrioxamine therapy in beta-thalassemia patients.
    Zafeiriou DI; Kousi AA; Tsantali CT; Kontopoulos EE; Augoustidou-Savvopoulou PA; Tsoubaris PD; Athanasiou MA
    Pediatr Neurol; 1998 May; 18(5):420-4. PubMed ID: 9650683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron chelating in thalassaemia with left ventricular dysfunction.
    Cagirci G; Tufekcioglu O; Yetim M
    Heart; 2006 Oct; 92(10):1440. PubMed ID: 16973798
    [No Abstract]   [Full Text] [Related]  

  • 24. Pregnancy and lactation in homozygous beta-thalassemia major.
    Surbek DV; Glanzmann R; Nars PW; Holzgreve W
    J Perinat Med; 1998; 26(3):240-3. PubMed ID: 9773387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of skeletal dysplasia in thalassaemia major.
    Naselli A; Vignolo M; Di Battista E; Garzia P; Forni GL; Traverso T; Aicardi G
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():817-25. PubMed ID: 10091152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
    Cianciulli P; Sorrentino F; Forte L; Palombi M; Papa G; Meloni C; Taccone Gallucci M; Casciani CU
    Haematologica; 1992; 77(6):514-5. PubMed ID: 1289188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia.
    La Rosa M; Romeo MA; Di Gregorio F; Russo G
    J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):127-8. PubMed ID: 8568125
    [No Abstract]   [Full Text] [Related]  

  • 30. Desferrioxamine related maculopathy: a case report.
    Arora A; Wren S; Gregory Evans K
    Am J Hematol; 2004 Aug; 76(4):386-8. PubMed ID: 15282675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity.
    Porter JB; Faherty A; Stallibrass L; Brookman L; Hassan I; Howes C
    Ann N Y Acad Sci; 1998 Jun; 850():483-7. PubMed ID: 9668591
    [No Abstract]   [Full Text] [Related]  

  • 32. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M; Di Bella D; Pizzarelli G; Leonardi C; Sciuto C; Coco M; Di Gregorio F
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe infections in thalassaemic patients: prevalence and predisposing factors.
    Rahav G; Volach V; Shapiro M; Rund D; Rachmilewitz EA; Goldfarb A
    Br J Haematol; 2006 Jun; 133(6):667-74. PubMed ID: 16704445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major.
    Christoforidis A; Perifanis V; Athanassiou-Metaxa M
    Br J Haematol; 2006 Oct; 135(2):271-2. PubMed ID: 16965387
    [No Abstract]   [Full Text] [Related]  

  • 36. Multimodal imaging in a case of deferoxamine-induced maculopathy.
    Gelman R; Kiss S; Tsang SH
    Retin Cases Brief Rep; 2014; 8(4):306-9. PubMed ID: 25372534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients.
    Costagliola DG; de Montalembert M; Lefrère JJ; Briand C; Rebulla P; Baruchel S; Dessi C; Fondu P; Karagiorga M; Perrimond H
    Br J Haematol; 1994 Aug; 87(4):849-52. PubMed ID: 7986727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.
    Marsh MN; Holbrook IB; Clark C; Shaffer JL
    Postgrad Med J; 1981 Sep; 57(671):582-4. PubMed ID: 7329898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.
    Miller TT; Caldwell G; Kaye JJ; Arkin S; Burke S; Brill PW
    Pediatr Radiol; 1993; 23(7):523-4. PubMed ID: 8309753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The radiological appearances of thalassaemia.
    Tyler PA; Madani G; Chaudhuri R; Wilson LF; Dick EA
    Clin Radiol; 2006 Jan; 61(1):40-52. PubMed ID: 16356815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.